Blog

  • Zoning board up next for Rockford apartments plan

    A development team from Indiana and New York wants to build a 158-unit apartment complex on Rockford’s south side near the intersection of 11th Street and Sandy Hollow Road, but the city says the proposal conflicts with long-range plans.

    LandWhite Developers LLC has put together a $17.6 million proposal to build the rental units, called The Village of Southgate, and improve the parking lot and facade of the shopping center just north of where it wants to build six apartment buildings. The team wants to obtain $12.2 million from the U.S. Department of Housing and Urban Development and $4.6 million from state housing tax credits. It plans to spend $800,000 of its own money, said LandWhite partner David Roos, and has an option on 6.9 acres where it intends to build.

    Roos and his partners plan to take their proposal to the city’s Zoning Board of Appeals tonight despite a thumbs-down recommendation from city staff.

    “We have a strong market study that came back very positive. We’ve got commitments from some of our lenders. The missing link is the (city’s approval of a planned unit development application),” Roos said Monday. “We’ve had positive conversations with the city, and we believe we’ve addressed their concerns.”
    Not appropriate land use

    Todd Cagnoni, deputy director of Rockford’s Community and Economic Development Department, said the city’s denial remains based on the proposal’s inconsistency with its land use plan.

    “It’s not that these developers haven’t made an effort to appropriately design their development,” Cagnoni said. “The fundamental concern of staff is that it’s not the appropriate land use. It’s not consistent with our 2020 plan, nor is it consistent with the TIF plan that we’ve adopted for that area. We’re looking for more commercial and industrial uses to go in that area rather than residential.”

    Going against the city’s plan can cause problems down the road, Cagnoni added.

    “Once you start going against the land use plan, you start taking opportunities away from commercial development that you’d like to see in the future, and you’re setting the stage that it’s going to be a residential development and we’re going to have to provide the services that we typically provide for residential, which is not planned for that particular area.”

    But Roos argued that the current zoning classification would allow for a residential development. He said he’s asking the zoning board for height and setback variances.

    Rents of $630 to $930
    The one- to three-bedroom units would rent for $630 to $930 a month, Roos said, and the development would bring hundreds of construction jobs to the area.

    Because of the types of funding that LandWhite hopes to obtain, The Village would need to rent 80 percent of its units to people who meet income eligibility requirements, Roos said. The remaining 20 percent would be market rate, he said.

    LandWhite also is putting together a proposal for the redevelopment of Church School on Rockford’s west side.

    Staff writer Corina Curry can be reached at [email protected] or 815-987-1371.

    Read the original article from the Rockford Register Star.

    Distributed via Chicago Press Release Services


  • Citroen to debut 17.4 foot long Metropolis concept at Beijing Motor Show

    citroen metropolis hybrid sedan concept

    Eco Factor: Low-emission vehicle powered by a hybrid engine.

    Citroen has announced that the company will be showcasing its new Metropolis concept at the Beijing Auto Show. The 17.4 foot long sedan will be powered by a hybrid engine ensuring carbon emissions as low as 70 grams per kilometer.

    (more…)

  • Sigma(R) Life Science Introduces CompoZr(R) Targeted Integration Kit for Controlled Transgene Expression in Human Cell Lines

    ST. LOUIS, April 20 /CHICAGOPRESSRELEASE.COM/ — Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich® (Nasdaq: SIAL), today announced an extension to its award-winning CompoZr® product offering with the global release of the CompoZr Targeted Integration Kit, AAVS1 (www.sigma.com/aavs1).  This kit provides a powerful method for the controlled transgene integration and expression of any gene in any human cell line using Sigma-Aldrich’s proprietary CompoZr Zinc Finger Nuclease (ZFN) technology.

    Specifically, the CompoZr Targeted Integration Kit enables users to rapidly integrate their gene of interest into a single locus on human chromosome 19, from where it will be expressed in a stable manner. Unlike other methods for transgene expression in human cells, this kit enables users to study their gene in the cell line of their choice, providing stable, uniform protein expression while eliminating the need to engineer cell lines with transgene landing pads.

    “Our new Targeted Integration Kit provides a valuable tool for scientists working with all types of human cells, including stem cells,” said Patrick Sullivan, vice president of Research and Development for Sigma-Aldrich’s Research Biotech business unit.  ”Similar to what the Rosa26 locus has done for transgenic research in mice, we believe the AAVS1 locus will provide a ’safe harbor’ site from which to study gene function and expression.  The kit, using Zinc Finger Nuclease technology, enables researchers to insert any gene construct into the human genome. This new kit is an exciting addition to our offering of CompoZr products, and will facilitate the construction of isogenic cells with permanent, stable gene expression.”

    The CompoZr Targeted Integration Kit offers a number of benefits over current methods of transgene expression in human cells. Traditional use of random insertion to introduce a DNA construct into the human genome may lead to gene disruption, variable epigenetic effects on transgene expression and presence of an unknown number of integrants in each cell, making comparisons difficult between isolated single cell clones. The CompoZr Targeted Integration Kit uses a ZFN to target the transgene specifically into the AAVS1 locus in the human genome leading to mono- or bi-allelic insertions enabling the stable expression and study of transgenes in cell lines where the number of integrants and the locus of integration is controlled by the researcher.  

    More information on Sigma-Aldrich’s CompoZr ZFN technology platform can be accessed by visiting www.compozrzfn.com, part of the recently-launched ‘Where Bio Begins’ brand and website (www.wherebiobegins.com).  ’Where Bio Begins’ is a leading digital destination where the biological research community can directly access the deep biological knowledge they require for their research, while driving awareness of Sigma-Aldrich’s strengths in providing products and technologies that facilitate scientists’ understanding of how diseases develop and how molecules function.

    Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as “provides a valuable tool,” “will provide a safe harbor site,” “enables researchers,” “offers a number of benefits” or similar expressions, or by express or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the CompoZr Targeted Integration Kit will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of the CompoZr Targeted Integration Kit will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding the CompoZr Targeted Integration Kit could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich brand that represents Sigma’s leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

    About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

    CompoZr, Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

    SOURCE Sigma-Aldrich

    http://www.sigma-aldrich.com

    Distributed via Chicago Press Release Services


  • Volkswagen unveils taxi vehicle concept at Hanover Trade Show

    volkswagen milan taxi_1

    Eco Factor: Zero-emission vehicle designed to run on electricity.

    Volkswagen has unveiled a new taxi vehicle concept at the Hanover Trade Show that has been designed for the city of Milan. The van-sized cab is powered by lithium ion batteries that provide an estimated range of 186 miles. The vehicle features a single rear door on the passenger side which can slide completely to make enough space for getting in and out.

    (more…)

  • Business Development – Solar

    London, Nottingham, Acre Resources

    My client, a specialist provider of low carbon turnkey electrical energy solutions, is currently entering a growth stage and is looking to add a number of Sales Executives to join their team to help drive this expansion.

    With a client focused business model, this company provides renewable energy solutions to commercial and domestic clients across the UK.

    This role will suit a driven and enthusiastic sales professional. Further to this the ideal candidate will have:

    • Demonstrable knowledge of renewable energy or low carbon business
    • A background within sales and an ability to meet targets
    • Knowledge of the low carbon sector and factors that affect this

    This company is offering the ideal candidates a competitive package, an opportunity to develop within a growing company and sector, and flexible working arrangements.

    Due to the high response we receive to adverts we are only able to respond to applicants closely matching the criteria.

  • Early Detection Techniques Change the Dynamics of the Systemic Fungal Infection Therapeutics Market, Finds Frost & Sullivan

    SINGAPORE, April 20 /CHICAGOPRESSRELEASE.COM/ — Over the next five years, technological advancements in therapeutics are expected to amplify the number of patients diagnosed with systemic fungal infection (SFI) in Thailand. The significant increase in number of patients is shifting the focus of managing SFI from empiric and prophylactic methods to targeted and pre-emptive treatment.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

    New analysis from Frost & Sullivan (http://www.pharma.frost.com), Systemic Fungal Infection Therapeutics Market – Thailand, estimates that the global prevalence of SFI has risen to four for every one thousand of the global population. Similarly, the incidence of SFI has increased steadily over the years due to the widespread use of broad-spectrum antibiotics, which reduce non-pathogenic bacterial population that compete with fungi, and the increased number of persons with compromised immune systems caused by AIDS, immunosuppressant drugs, and chemotherapy agents.

    The SFI therapeutics market is also likely to receive a shot in the arm with a high premium on products that are capable of tackling emergent, problematic pathogens. As more resistant pathogens in SFI emerge, therapy will revolve around ensuring that the right treatment is administered. This is made possible through non-microbiologic and clinical diagnostic techniques (Platelia, Fungitell, and PNA FISH®) to identify the onset of infection.

    Although there are key therapeutics to treat the most causative pathogen (Candida Albicans), there is still an unmet need to treat more resistant pathogens such as Aspergillus. Doctors are under increasing pressure to ensure that they choose the right course of treatment the first time, based on the universal criteria of risk factors, clinical, radiological, microbiological, or other diagnostic evidence.

    “This places greater emphasis on matching antifungal choice to pathogen susceptibility, increasing the demand for rapid typing of pathogens to ensure informed, targeted drug choices,” says Frost & Sullivan Program Manager Carole Gaffud. “As a result, there would be a reduction in the use of prophylaxis in the ‘at risk’ patient group, and empiric therapy in patients groups with a persistent fever or other suggestive symptoms.”

    Given the relatively niche nature of SFI, it is important for key participants to differentiate their products, especially as advancements in diagnostic techniques restrict prescriptions to specific therapeutic uses. As therapeutics shift from broad and empiric indications, pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and subspecies) and patient population. This enables greater differentiation, thereby protecting the specific drug from generic erosion in the future.

    “The changing epidemiology of causative pathogens has caused a decline in the effectiveness of existing therapeutic options,” notes Gaffud. “Pharmaceutical manufacturers need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups (solid organ transplant patients, cancer patients, neonates, HIV/AIDS patients, and surgery patients).”

    If you are interested in more information on this study, please send an e-mail to Nicklaus Au, Corporate Communications, at [email protected] and [email protected] with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

    Systemic Fungal Infection Therapeutics Market – Thailand is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: The Systemic Fungal Infection Therapeutics Market in Hong Kong, The Systemic Fungal Infection Therapeutics Market in China, The Systemic Fungal Infection Therapeutics Market in Australia, The Systemic Fungal Infection Therapeutics Market in Singapore, The Systemic Fungal Infection Therapeutics Market in India, The Systemic Fungal Infection Therapeutics Market in Taiwan, The Systemic Fungal Infection Therapeutics Market in Malaysia, The Systemic Fungal Infection Therapeutics Market in the Philippines, and The Systemic Fungal Infection Therapeutics Market in South Korea. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

    About Frost & Sullivan

    Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    SOURCE Frost & Sullivan

    http://www.frost.com

    Distributed via Chicago Press Release Services


  • Chobi Cam is the new king of miniature cameras

    Chobi Cam is the new king of miniature cameras

    Not unlike the Mini-digi which we covered a few weeks back, the Chobi Cam from Japan Trust Technologies gives you the power to shoot photos and videos using a device no bigger than an eraser. Even smaller than the Mini-Digi (2.5 x 1.8 x 1.2 inches), the Chobi Cam measures a miniscule 1.7 x 1.1 x 0.5 inches and weighs only half an ounce…
    Continue Reading Chobi Cam is the new king of miniature cameras

    Tags: ,
    ,
    ,

    Related Articles:


  • Next iPhone revealed?

    Gizmodo has been closely examining what it believes is the next iPhone.

    Apple’s notoriously tight secrecy ahead of product launches seems to have been undermined with a stray prototype of what appears to be the next iPhone falling into the eager hands of Gizmodo. It’s been carefully pulled-apart, pored-over and examined from every angle, and the folks over at Gizmodo are convinced that it’s the real thing. So what can we expect?..
    Continue Reading Next iPhone revealed?

    Related Articles:


  • College-Bound Texas Teens Face Budget Squeeze; Many Alter Education Plans

    HOUSTON, April 20 /CHICAGOPRESSRELEASE.COM/ — As incoming college freshmen prepare to turn in their acceptance letters on May 1, many families are scrambling to figure out how to fund their teens’ education. Nearly one-in-two (45 percent) Houston-area teens surveyed indicated they had changed their college plans because of the economy. This is among the key findings in the Houston-area administered 2010 Junior Achievement/Allstate Foundation “Teens and Personal Finance” Survey.

    Included within the 45 percent whose college plans have changed, 16 percent are working more to pay for college, 14 percent are staying closer to home or are not attending college out of state, 9 percent plan on going to a community college, 4 percent may delay school for one year or longer and 2 percent are not planning to go to college.

    Economic pressures and steadily increasing tuition are forcing teens and their families to exercise financial discipline to pay college costs. A majority of Houston-area teens—55 percent—report they and their families are saving for college, with 20 percent of those teens saving their own money and 35 percent reporting their parents are saving for their college educations. However, nearly one-in-five (17 percent) haven’t determined how they will pay for college.

    Interestingly, 44 percent of Houston-area teens say they plan on getting college scholarships. Yet, 66 percent of all U.S. undergraduates received some type of financial aid in 2007–08, including grants, loans and scholarships, according to the U.S. Department of Education. Those who miss out on financial aid opportunities will be left with tough financial decisions to make.

    Of those students nationwide who do receive some type of financial aid, U.S. Department of Education data show that the median amount of student-loan debt carried by 2007-08 bachelor’s degree recipients at public four-year colleges was $17,700 and $22,375 at private four-year institutions.

    This debt level has taken its toll on students’ ability to repay their loans, as evidenced in the rise of student-loan default rates. The latest data from the U.S. Department of Education show that default rates are up from 5.2 percent in 2006 to 6.7 percent in 2007.

    Considering that nearly seven percent of college graduates across the country default on their student loans, it is imperative that teens weigh their ability to service their student loans when making college and career choices—equally important are solid financial planning.

    “Junior Achievement aims to provide students with a strong set of money-management skills, so they can effectively budget, use credit, and save,” noted Rick Franke, president of Junior Achievement of Southeast Texas. “Since April is Financial Literacy Month, it is a great time to reinforce the importance of those skills.”

    Junior Achievement and The Allstate Foundation have partnered to create Junior Achievement, $ave USA, a financial literacy initiative comprised of free, downloadable money management exercises for parents and their children to do together.

    For a full survey abstract, contact Kevin R. Hattery at [email protected].

    SOURCE Junior Achievement of Southeast Texas

    http://houston.ja.org

    Distributed via Chicago Press Release Services


  • Suspended Public Transportation System feeds itself with renewable energy

    suspended public transportation system_2

    Eco Factor: Sustainable monorail concept powered by renewable energy.

    The Suspended Public Transportation System designed by Elisa Sayuri Freitas Irokawa and Rafael Osmar de Oliveira e Costa could well be the greenest train design ever. The hanging monorail let you behold the scenic beauty of a futuristic city and the ride is also carbon-neutral with solar and wind generators doing the job.

    (more…)

  • Batman voice actor: Arkham Asylum 2 is "really, really dark", will feature …

    Rocksteady has already made the promise that Batman: Arkham Asylum 2 won’t let anyone down. Now, Batman’s voice actor, Kevin Conroy, reveals that it will be “really, really dark.”
     
     
     
     

  • Largest-ever Global Sources India Sourcing Fair: Home Products opens today in Hong Kong at AsiaWorld-Expo

    Global Sources is also launching new Made in India show in Dubai this June to meet rising demand in the Middle East for products from India

    HONG KONG, April 20 /CHICAGOPRESSRELEASE.COM/ — Global Sources’ ( GSOL)
    largest-ever India Sourcing Fair: Home Products (http://www.india-
    sourcingfair.com ) opened today at AsiaWorld-Expo in Hong Kong and runs until
    April 23.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20030303/LNM011LOGO-b )

    The Fair offers international buyers more than 110 booths of India
    suppliers displaying their latest handicrafts, kitchenware, glassware and
    metalware, home decor, home textiles, jute and paper products.

    Reflecting the increasing demand for products from India, the spring 2010
    show has 10 percent more booths than Global Sources’ debut India Sourcing
    Fair: Home Products held in Hong Kong in April 2009.

    “The show’s expansion this year provides suppliers from India with greater
    sales opportunity and exposure,” said Tommy Wong, President of Global Sources
    Exhibitions. “Thousands of buyers are drawn to this Fair, as it is a
    world-class exhibition for unique products from quality India suppliers — all
    in the convenience of Hong Kong.

    “India’s exports in February surged by 34.8 percent year-on-year to $16.1
    billion. That follows growth of 11.5 percent in January this year and 9.3
    percent last December. With demand for India’s exports around the world
    rebounding, this is clearly the time for India suppliers to exhibit at the
    Fair and meet face-to-face with buyers.”

    India suppliers and export federation embrace opportunities Fair offers

    Exhibitors are responding well to the Hong Kong show. Mohammed Adil
    Shamsi, Managing Director of Giftmark Industries, said: “The India Sourcing
    Fair is a great chance for us to secure more orders. That is a vital sales
    channel for us to benefit from the rebound in global demand.”

    The Federation of Indian Export Organisations (FIEO) supports Global
    Sources’ India Sourcing Fair. The FIEO is the apex body of all Indian
    export-promotion organizations, and the Indian government’s partner in
    promoting the country’s international business.

    O. P. Garg, FIEO committee member, will address buyers at the show’s
    “Made-in-India: A market snapshot” seminar. The seminar provides insight
    valuable in helping buyers source more effectively from suppliers in India. It
    is scheduled for April 20 from 4:30 to 5:30 p.m. in room 201B of
    AsiaWorld-Expo.

    Made in India show set for June launch in Dubai

    The Hong Kong event also sets the stage for the new Made in India — India
    Sourcing Fair scheduled for June 8-10 in Dubai. This event is expected to be
    the first-ever exhibition of quality Indian products in the United Arab
    Emirates. India exporters have already booked 250 booths at the Dubai show.

    Wong said: “We are taking Indian suppliers to the world’s top sourcing
    centers, particularly Hong Kong and Dubai, to give them access to leading
    international buyers. As the economic recovery strengthens, it is important
    for Indian suppliers to reconnect with current buyers and seek new markets.”

    For more information on India Sourcing Fair, visit
    http://www.india-sourcingfair.com .

    About Global Sources

    Global Sources is a leading business-to-business media company and a
    primary facilitator of trade with Greater China. The core business uses
    English-language media to facilitate trade from Greater China to the world.
    The other business segment utilizes Chinese-language media to enable companies
    to sell to, and within Greater China.

    The company provides sourcing information to volume buyers and integrated
    marketing services to suppliers. It helps a community of over 888,000 active
    buyers source more profitably from complex overseas supply markets. With the
    goal of providing the most effective ways possible to advertise, market and
    sell, Global Sources enables suppliers to sell to hard-to-reach buyers in over
    240 countries.

    The company offers the most extensive range of media and export marketing
    services in the industries it serves. It delivers information on 4.5 million
    products and more than 253,000 suppliers annually through 14 online
    marketplaces, 13 monthly magazines, over 80 sourcing research reports and 17
    specialized trade shows which run 55 times a year across 10 cities.

    Suppliers receive more than 136 million sales leads annually from buyers
    through Global Sources Online (http://www.globalsources.com ) alone.

    Global Sources has been facilitating global trade for 39 years. Global
    Sources’ network covers more than 60 cities worldwide. In mainland China,
    Global Sources has about 2,500 team members in more than 40 locations, and a
    community of over 1 million registered online users and magazine readers for
    its Chinese-language media.

        Global Sources Press Contact in Asia:
         Camellia So
         Tel:   +852-2555-5021
         Email: [email protected]
    
        Global Sources Press Contact in U.S.:
         James W.W. Strachan
         Tel:   +1-480-664-8309
         Email: [email protected]
    
        Global Sources Investor Contact in Asia:
         Investor Relations Department
         Tel:   +852-2555-4777
         Email: [email protected]
    
        Global Sources Investor Contact in U.S.:
         Kirsten Chapman & Timothy Dien
         Lippert/Heilshorn & Associates, Inc.
         Tel:   +1-415-433-3777
         Email: [email protected]
    

    SOURCE Global Sources

    http://www.globalsources.comhttp://www.india-sourcingfair.com

    Distributed via Chicago Press Release Services


  • What Cooling? China’s Speculative Inflows Accelerate In March

    Beijing China Hot Pot

    An economist from the Chinese Academy of Social Sciences (CASS) believes that speculative capital inflows into China have intensified most recently.

    The prospect of an imminent upwards yuan adjustment could be trumping efforts to cool the Chinese economy and temper liquidity growth in the financial system:

    China Daily:

    “Calculations show that in March, such capital inflows expanded dramatically compared with the previous two months,” Zhang Ming, an economist at the Institute of World Economics and Politics at CASS, told China Daily. “It could be a new trend.”

    “The relatively higher domestic interest rate and moderately rising expectations of yuan appreciation will lead to the scaling up of cross-border carry trade,” SAFE said in a report on its international balance of payments.

    Zhang said that unexplainable capital inflows into China in the first three months amounted to $5.6 billion, $5.7 billion and $20.5 billion respectively.

    The calculation was conducted through subtracting the country’s monthly foreign exchange reserves by its trade surplus, foreign direct investment, valuation effects caused by currency exchange rate changes and investment returns, which is believed to be a quite comprehensive methodology.

    “In the coming six months, short-term international capital may continue to flow into China, which would put more sterilization pressure on the central bank and push up domestic consumer goods and real estate prices,” he said.

    Read more here >

    Join the conversation about this story »

  • Should Managers Care That Employees Are On Facebook And YouTube While At Work?

    A recent study reported that 6.8 percent of URLs accessed by businesses lead to Facebook and 10 percent of bandwidth goes to YouTube. Of course, as to be expected, along with such a study come the fears that security and worker productivity is harmed by allowing access to such “non-work” sites:


    The figures show that IT managers are right to be concerned about the amount of social network use at work. There are two real concerns here: firstly that employees will be downloading applications from social networks and putting security at risk; and secondly the amount of corporate bandwidth that appears to be being used for non-corporate activity.

    These fears seem to resurface every once in awhile, especially when some new technology starts to become ubiquitous in the workplace. First, it’s silly to think that social networks would somehow have more security-risking applications to download than the rest of the internet. As for the productivity concern, if you’re worrying about how much time your employees are spending doing “non-work” things, then you’re worrying about the wrong thing. From online shopping to social networking, allowing employees to do “non-work” web surfing while they are at the office keeps them happier and more productive. In fact, multiple studies have shown that social media sites like Twitter and Facebook actually make workers more productive by sparking creative ideas.

    Of course, in order to manage this properly, managers must monitor productivity based on concrete, measurable goals — rather than focus on the time spent doing the work. After all, if you’re delivering results, why should your manager care if you spend a few minutes a day catching up with friends on Facebook?

    Permalink | Comments | Email This Story





  • Apple To Gizmodo: You’ve Had Your Fun, Hand Over The Phone


    iPhone 4

    A few weeks after requiring iPad developers to work with devices chained to tables in windowless rooms, famously secretive Apple is in the awkward position of having to ask Gawker Media’s Gizmodo oh, so politely to give back an iPhone prototype left in a bar. No threats over buying misbegotten goods (yet) or any confirmation that what Gizmodo acquired for $5,000 is actually a prototype of the iPhone 4G. Just a few simple sentences in a letter to Gizmodo Editorial Director Brian Lam from Apple General Counsel Bruce Sewell, then posted on the gadget blog’s site: “It has come to our attention that Gizmodo is currently in possession of a device that belongs to Apple (NSDQ: AAPL). This letter constitutes a formal request that you return the device to Apple. Please let me know where to pick up the unit.”

    The letter, writes Lam, was the result of phone calls asking for the device and his insistence that it be claimed on the record. That in turn gave him the chance to claim Gizmodo had no idea that device was stolen when they bought it; “Now that we definitely know it’s not some knockoff, and it really is Apple’s, I’m happy to see it returned to its rightful owner.” This is the capper to an odd series of events that started when a hapless Apple employee—outed Monday by Gizmodo—had a beer too many at a bar in Redwood City Mar. 18 and left his iPhone behind. A fellow bar patron, who took it instead of turning it over to the bar as lost, later opened the case and discovered the iPhone 3GS actually was covering another device. He told Gizmodo he saw the Apple employee’s Facebook page on the iPhone before it was wiped and tried unsuccessfully to return the device to Apple.

    The phone was wiped via the MobileMe’s “lost” feature, keeping Gizmodo and others from trying it as a phone or with iTunes, But the site gave the device a thorough tech review, zoning in on a micro-SIM card; a front camera with flash; a new, more industrial design; and what looks like efforts to improve reception.

    Was it worth the $5,000? That, and then some in publicity/traffic. At last check, just one of the posts had more than 28,000 tweets, more than 3.7 million page views and more than 1,870 comments. Understandable from Gizmodo’s perspective. Does that make the whole incident—and the paycheck journalism involved—feel any less, well, slithery? Not so much. Wish they’d been able to get the scoop without buying something they had to know the seller didn’t have the right to.

    Meanwhile Apple, which reports earnings Tuesday afternoon, confirmed that Gizmodo had its device but not what it was or what level of prototype it might be. That’s a whiteboard for investors and analysts to scribble on as they try to decide how to factor in the next-gen iPhone.

    Related


  • ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion (VMA)

    LEUVEN, Belgium, April 20, 2010 /CHICAGOPRESSRELEASE.COM/ –

    – Highly Significant Trial Result (p=0.003) Demonstrates the Potential of
    Microplasmin in the Treatment of Retinal Disease

    ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company
    focused on the discovery and development of innovative treatments for eye
    disease, vascular disease and cancer, announces that its first Phase III
    trial with microplasmin for the non-surgical treatment of eye disease has met
    its primary endpoint (p=0.003). The trial, TG-MV-006, recruited a total of
    326 patients in the U.S. A second Phase III study with microplasmin,
    TG-MV-007, which recruited a similar number of patients in the U.S. and
    Europe, is due to report in the third quarter of 2010.

    The microplasmin Phase III program, referred to as MIVI-TRUST
    (Microplasmin for IntraVitreous Injection-Traction Release without Surgical
    Treatment), consists of two multi-center, randomized, placebo controlled,
    double-masked trials. These trials are designed to evaluate 125μg of
    microplasmin versus placebo in the intravitreal treatment of patients with
    symptomatic focal vitreomacular adhesion (VMA). The MIVI-TRUST program is the
    largest interventional clinical program ever performed to specifically
    evaluate the vitreoretinal interface in patients with retinal disorders.

    The primary endpoint of both trials is the non-surgical resolution of
    focal vitreomacular adhesion one month after a single injection of
    microplasmin. This endpoint is being measured and recorded using optical
    coherence tomography (OCT), the standard method of assessment for this
    condition, which provides images that can clearly show the separation of the
    vitreous from the retina.

    The results of the first trial, TG-MV-006, confirmed that it had met its
    primary endpoint with 27.7% of microplasmin treated patients achieving
    resolution of their VMA compared to 13.2% of patients treated with placebo
    injection (p=0.003). A Per Protocol analysis of the microplasmin treated
    patient population showed that 30.7% achieved resolution of their VMA
    (p=0.004).

    In addition to the primary endpoint, the Phase III trials will evaluate
    additional measures of efficacy as well as safety, assessed at various time
    periods over the six month study period. These data will be presented at the
    World Ophthalmology Congress (WOC) in Berlin by Dr. Matthew Benz, MD (Baylor
    College of Medicine, Houston, Texas, U.S.).

    Dr. Patrik De Haes, CEO of ThromboGenics, commented, “This is the most
    important milestone in ThromboGenics’ history. Microplasmin is key to the
    success of our ophthalmic focused strategy, and we are very pleased to be
    able to announce these positive results. The fact that microplasmin resolved
    VMA without surgery in approximately 30% of patients is a clinically
    important development. These results reaffirm our confidence in the potential
    of this innovative approach to the treatment of a range of retinal disorders.
    We are moving ahead with our pre-commercialization activities for
    microplasmin, so that we are well-positioned to launch this unique product
    successfully.”

    About Focal Vitreomacular Adhesion (VMA)

    Focal vitreomacular adhesion is a condition in which the vitreous gel, in
    the center of the eye, has an abnormally strong adhesion to the macula, the
    center of the retina at the back of the eye. Vitreomacular adhesion is
    thought to play a key role in numerous back of the eye conditions, such as
    macular hole and some forms of macular edema. Vitreomacular adhesion is also
    associated with a poorer prognosis in certain major eye conditions, including
    Diabetic Retinopathy and Age-related Macular Degeneration (AMD).

    About ThromboGenics

    ThromboGenics is a biopharmaceutical company focused on the discovery and
    development of innovative medicines for the treatment of eye disease,
    vascular disease and cancer. The Company’s lead product microplasmin has
    completed its first Phase III clinical trial for the non-surgical treatment
    of back of the eye diseases. Microplasmin is also being evaluated in Phase II
    clinical development for additional vitreoretinal conditions. In addition,
    ThromboGenics is developing novel antibody therapeutics in collaboration with
    BioInvent International; these include TB-402 (anti-Factor VIII), a long
    acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase I for
    cancer.

    ThromboGenics is headquartered in Leuven, Belgium. The Company is listed
    on Eurolist by Euronext Brussels under the symbol THR. More information is
    available at http://www.thrombogenics.com.

    Important information about forward-looking statements

    Certain statements in this press release may be considered
    “forward-looking”. Such forward-looking statements are based on current
    expectations, and, accordingly, entail and are influenced by various risks
    and uncertainties. The Company therefore cannot provide any assurance that
    such forward-looking statements will materialize and does not assume an
    obligation to update or revise any forward-looking statement, whether as a
    result of new information, future events or any other reason. Additional
    information concerning risks and uncertainties affecting the business and
    other factors that could cause actual results to differ materially from any
    forward-looking statement is contained in the Company’s Annual Report.

        For further information please contact:
    
        ThromboGenic
        Dr. Steve Pakola, CMO                     Tel: +1(212)201-0920
                                                  [email protected]
    
        Dr. Patrik De Haes, CEO                   Tel: +32-16-75-13-10
                                                  [email protected]
    
        Citigate Dewe Rogerson
        Amber Bielecka/ David Dible/ Nina Enegren Tel: +44(0)207-638-95-71
                                                  [email protected]
    

    SOURCE ThromboGenics NV

    Distributed via Chicago Press Release Services


  • One massive 3D printer

    I”ve been doing a lot of blogging about the SculptCAD Rapid Artist Project lately, and that involves artists creating digital sculpture using 3D modeling software and then printing the artwork with a 3D printer. These works were limited in size to something you could wrap your arms around.

    This 3D printer is many orders of magnitude larger than any I’ve ever encountered. Very cool, and with very interesting potential uses.

    From the second link:

    3D printer could build moon bases

    3D printer could build moon bases

    An Italian inventor, Enrico Dini, chairman of the company Monolite UK Ltd, has developed a huge three-dimensional printer called D-Shape that can print entire buildings out of sand and an inorganic binder. The printer works by spraying a thin layer of sand followed by a layer of magnesium-based binder from hundreds of nozzles on its underside. The glue turns the sand to solid stone, which is built up layer by layer from the bottom up to form a sculpture, or a sandstone building.

    The D-shape printer can create a building four times faster than it could be built by conventional means, and reduces the cost to half or less. There is little waste, which is better for the environment, and it can easily “print” curved structures that are difficult and expensive to build by other means. Dini is proving the technology by creating a nine cubic meter pavilion for a roundabout in the town of Pontedera.

    Hit the second link for video of a 3D printer in action.

  • Navy Develops Battery that Runs on Mud

    The Office of Naval Research will highlight their microbial fuel cell that was one of TIME magazine’s “Top 50 Inventions of 2009” for an Earth Day event on April 22.

    According to Peter Vietti of the Office of Naval Research the microbial fuel cell is a device “that could revolutionize naval energy use by converting decomposed marine organisms into electricity.”

    By converting naturally occurring fuels and oxidants in the marine environment into electricity, Naval vessels could be running on a clean and efficient reliable alternative battery avoiding the harmful impact that standard batteries and fuels have upon the marine environment. (more…)

  • DS homebrew game – Pokemon Battle v0.6

    Here is the latest version of blabla’s homebrew project, Pokemon Battle, a homebrew RPG game for the Nintendo DS based on the popular anime series. The latest update of the homebrew has added some new features, more